
Catharine I Paules

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9863295/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Coronavirus Infections—More Than Just the Common Cold. JAMA - Journal of the American Medical Association, 2020, 323, 707.	7.4	1,501
2	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. New England Journal of Medicine, 2021, 384, 795-807.	27.0	1,398
3	Influenza. Lancet, The, 2017, 390, 697-708.	13.7	550
4	A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. Journal of Infectious Diseases, 2018, 218, 347-354.	4.0	333
5	Chasing Seasonal Influenza — The Need for a Universal Influenza Vaccine. New England Journal of Medicine, 2018, 378, 7-9.	27.0	213
6	Measles in 2019 — Going Backward. New England Journal of Medicine, 2019, 380, 2185-2187.	27.0	127
7	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 1365-1376.	10.7	119
8	Yellow Fever — Once Again on the Radar Screen in the Americas. New England Journal of Medicine, 2017, 376, 1397-1399.	27.0	113
9	Monoclonal Antibodies for Emerging Infectious Diseases — Borrowing from History. New England Journal of Medicine, 2018, 378, 1469-1472.	27.0	108
10	Tickborne Diseases — Confronting a Growing Threat. New England Journal of Medicine, 2018, 379, 701-703.	27.0	98
11	Expression of the Helicobacter pylori adhesin SabA is controlled via phase variation and the ArsRS signal transduction system. Microbiology (United Kingdom), 2008, 154, 2231-2240.	1.8	72
12	Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 888-899.	10.7	62
13	The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses. Journal of Infectious Diseases, 2017, 216, 356-365.	4.0	46
14	Influenza Vaccines: Good, but We Can Do Better. Journal of Infectious Diseases, 2019, 219, S1-S4.	4.0	46
15	What Recent History Has Taught Us About Responding to Emerging Infectious Disease Threats. Annals of Internal Medicine, 2017, 167, 805.	3.9	33
16	The Critical Role of Biomedical Research in Pandemic Preparedness. JAMA - Journal of the American Medical Association, 2017, 318, 1757.	7.4	27
17	COVID-19: The therapeutic landscape. Med, 2021, 2, 493-497.	4.4	20
18	Emerging and Reemerging Infectious Diseases. JAMA - Journal of the American Medical Association, 2017, 317, 691.	7.4	17

CATHARINE I PAULES

#	Article	IF	CITATIONS
19	Physiologic Response to the Pfizer-BioNTech COVID-19 Vaccine Measured Using Wearable Devices: Prospective Observational Study. JMIR Formative Research, 2021, 5, e28568.	1.4	13
20	Association Between Human Immunodeficiency Virus Infection and Cardiovascular Diseases. JAMA Cardiology, 2017, 2, 123.	6.1	6
21	Influenza vaccination and prevention of cardiovascular disease mortality – Authors' reply. Lancet, The, 2018, 391, 427-428.	13.7	6
22	Long-term follow-up of post-cardiac surgery Mycobacterium chimaera infections: A 5-center case series. Journal of Infection, 2020, 80, 197-203.	3.3	6
23	Immunity to Influenza: Catching a Moving Target To Improve Vaccine Design. Journal of Immunology, 2019, 202, 327-331.	0.8	4
24	A Universal Flu Vaccine Is Vital. Scientific American, 2018, 318, 8-8.	1.0	2
25	Development of a Postexposure Biologic Treatment Algorithm on a Medical Center Campus. Journal of Public Health Management and Practice, 2013, 19, 366-370	1.4	0